Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

S B Kaye

Showing results (401-410 of 411) with videos related to

Pageof 42
Sort By:
British Journal of Cancer|August 23, 2012
Prediction of early death among patients enrolled in phase I trials: development and validation of a new model based on platelet count and albuminA Ploquin, D Olmos, D Lacombe, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|March 11, 2014
Outcome of patients with sarcoma and other mesenchymal tumours participating in phase I trials: a subset analysis of a European Phase I databaseP A Cassier, V Polivka, I Judson, et al.
ESMO Open|February 20, 2021
Cediranib in addition to chemotherapy for women with relapsed platinum-sensitive ovarian cancer (ICON6): overall survival results of a phase III randomised trialJ A Ledermann, A C Embleton-Thirsk, T J Perren, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 24, 1998
Population pharmacokinetics/pharmacodynamics of docetaxel in phase II studies in patients with cancerR Bruno, D Hille, A Riva, et al.
Investigational New Drugs|May 11, 2002
Population pharmacokinetic and dynamic analysis of the topoisomerase I inhibitor lurtotecan in phase II studiesJ H M Schellens, B Heinrich, M Lehnert, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 1, 1996
Mature results of a randomized trial of two doses of cisplatin for the treatment of ovarian cancer. Scottish Gynecology Cancer Trials GroupS B Kaye, J Paul, J Cassidy, et al.
Clinical and Experimental Allergy : Journal of the British Society for Allergy and Clinical Immunology|May 17, 2011
Harnessing engineered antibodies of the IgE class to combat malignancy: initial assessment of FcɛRI-mediated basophil activation by a tumour-specific IgE antibody to evaluate the risk of type I hypersensitivityS M Rudman, D H Josephs, H Cambrook, et al.
British Journal of Cancer|December 4, 1998
Chemotherapy for ovarian cancer--a consensus statement on standard practiceM Adams, A H Calvert, J Carmichael, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 16, 2001
Viable malignant cells after primary chemotherapy for disseminated nonseminomatous germ cell tumors: prognostic factors and role of postsurgery chemotherapy--results from an international study groupK Fizazi, S Tjulandin, R Salvioni, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|April 29, 1999
Advanced epithelial ovarian cancer: 1998 consensus statementsJ S Berek, K Bertelsen, A du Bois, et al.
Pageof 42

Showing results (401-410 of 411) with videos related to

Sort By:
Pageof 42
British Journal of Cancer|August 23, 2012
Prediction of early death among patients enrolled in phase I trials: development and validation of a new model based on platelet count and albuminA Ploquin, D Olmos, D Lacombe, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|March 11, 2014
Outcome of patients with sarcoma and other mesenchymal tumours participating in phase I trials: a subset analysis of a European Phase I databaseP A Cassier, V Polivka, I Judson, et al.
ESMO Open|February 20, 2021
Cediranib in addition to chemotherapy for women with relapsed platinum-sensitive ovarian cancer (ICON6): overall survival results of a phase III randomised trialJ A Ledermann, A C Embleton-Thirsk, T J Perren, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 24, 1998
Population pharmacokinetics/pharmacodynamics of docetaxel in phase II studies in patients with cancerR Bruno, D Hille, A Riva, et al.
Investigational New Drugs|May 11, 2002
Population pharmacokinetic and dynamic analysis of the topoisomerase I inhibitor lurtotecan in phase II studiesJ H M Schellens, B Heinrich, M Lehnert, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 1, 1996
Mature results of a randomized trial of two doses of cisplatin for the treatment of ovarian cancer. Scottish Gynecology Cancer Trials GroupS B Kaye, J Paul, J Cassidy, et al.
Clinical and Experimental Allergy : Journal of the British Society for Allergy and Clinical Immunology|May 17, 2011
Harnessing engineered antibodies of the IgE class to combat malignancy: initial assessment of FcɛRI-mediated basophil activation by a tumour-specific IgE antibody to evaluate the risk of type I hypersensitivityS M Rudman, D H Josephs, H Cambrook, et al.
British Journal of Cancer|December 4, 1998
Chemotherapy for ovarian cancer--a consensus statement on standard practiceM Adams, A H Calvert, J Carmichael, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 16, 2001
Viable malignant cells after primary chemotherapy for disseminated nonseminomatous germ cell tumors: prognostic factors and role of postsurgery chemotherapy--results from an international study groupK Fizazi, S Tjulandin, R Salvioni, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|April 29, 1999
Advanced epithelial ovarian cancer: 1998 consensus statementsJ S Berek, K Bertelsen, A du Bois, et al.
Pageof 42